Looking for Quit Genius? here's what happened, and what to do instead

Last reviewed 2026-07-27 · by the NOPE team at Bit Microsystems LLC

Quit Genius rebranded to Pelago and moved to a business-to-business model — sold through employers and health plans rather than downloaded directly — which is why searching for it as a consumer app turns up nothing to install.

If you searched for Quit Genius expecting to find it in the App Store or Google Play and came up empty, that's not a broken link or a discontinued product — it's a business model change. Quit Genius rebranded to Pelago and moved to a business-to-business model: virtual clinics sold through employers and health plans, rather than a consumer app anyone can download and pay for directly. That's the whole explanation for why a direct search doesn't turn up a download link the way it might have in the past.

What that means in practice

Pelago operates as a benefit that employers and health insurers offer to the people they cover, rather than as a product sold directly to individuals. If your employer or health plan happens to offer it, that's genuinely worth checking — a service like that, if it's included in a benefits package, is likely free to you, which is better value than paying anyone out of pocket, including us. We'd rather point you at a free benefit you already have access to than have you pay for something redundant.

We're not going to speculate about Pelago's clinical outcomes, pricing, or how it compares in effectiveness — we don't have that information, and it wouldn't be fair to either of us to guess. What we can say is that the shift from consumer app to employer-distributed clinic is a real, verifiable change in how the product is sold, and it's the reason a direct download search doesn't work anymore.

This kind of shift is fairly common in digital health: a product launches as something anyone can sign up for, proves itself, and then finds its most sustainable distribution channel is through the organizations that already pay for employee healthcare rather than through individual consumers paying app-store prices. It's not a sign the underlying service disappeared — it's a sign the business found a different buyer. For someone who just wants to quit smoking today, though, that distinction doesn't matter much if you don't have access to it through work; you still need something you can start using right now.

If a benefit like that isn't available to you

Plenty of people don't have an employer or health-plan benefit that covers something like Pelago, and need an option they can just pay for themselves. A few real paths, roughly in order of what's typically free or lowest-effort first:

1. Free
   A quitline
   In the US, 1-800-QUIT-NOW connects you to your state's free quit-coaching service. It's real coaching, at no cost, and it's worth calling before you pay for anything.
2. Ask a doctor
   Nicotine replacement therapy or prescription medication
   Patches, gum, lozenges, or prescription options can meaningfully improve your odds of quitting, and a doctor can help you choose one and cover it through insurance where possible.
3. $4.99/month
   A self-serve, taper-based app like NOPE
   If you want structure and daily tracking without going through an employer program or a clinician, a self-serve app is the direct route. NOPE builds a daily cigarette allowance that steps down to zero by a quit date you pick, logs every cigarette honestly (going over your allowance recalibrates the plan instead of punishing you), and opens a guided-breathing SOS room the moment a craving hits.

Those aren't mutually exclusive — plenty of people use a quitline or NRT alongside a tracking app. Where NOPE specifically fits is the self-serve, pay-it-yourself, taper-based lane: no employer sign-up, no waiting on a benefits enrollment window, just a 7-day free trial and then $4.99/month or $49.99/year if it's useful to you. It is not a clinical program and it makes no claim to replace one.

Quit Genius and Pelago are trademarks of their respective owners, referenced here only to identify the product people are searching for. We have no affiliation with either company, and nothing on this page should be read as a comparison of clinical outcomes — we're describing a business-model change, not rating one company against another.

Common questions